© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health
November 19, 2021
Sotrovimab, a monoclonal antibody, appears to reduce the risk of progression of mild-to-moderate cases of COVID-19 in patients at high risk of progression.
November 14, 2021
Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.
November 14, 2021
Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.
November 14, 2021
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
November 13, 2021
Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.
November 12, 2021
Peter J. McDonnell, MD, speaks on what attendees can look forward to at this year’s 2021 annual American Academy of Ophthalmology meeting in New Orleans.
November 12, 2021
Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.
November 04, 2021
Michael Rivers, MD, director of ophthalmology, Modernizing Medicine, shares what lingers on his mind in the field of ophthalmology at the end of the day.
October 21, 2021
JD Schaub, chief operating officer at RVL Pharmaceuticals, shares what lingers on his mind in the ophthalmic field at the end of the day.
